Ozempic Gastroparesis Lawsuit: What the MDL Hearing Means

If you took Ozempic, Wegovy, Mounjaro, or another GLP-1 medication and ended up with severe, unrelenting stomach problems, you have probably wondered whether the drug had anything to do with it. You may also have seen advertising about an Ozempic gastroparesis lawsuit and wondered whether any of it applies to you.

This month, a federal judge in Philadelphia is scheduled to take up the question that sits at the center of that litigation: whether the injured plaintiffs’ scientific experts may testify at all. Because that single ruling can decide whether thousands of cases move toward trial or quietly end, it is worth understanding what is happening.

Below is a plain-English look at where the GLP-1 litigation stands, what the claims actually allege, who may be eligible, and what to do if you were hurt. Nothing here is a prediction. The science in these cases is still being argued over in court.

What an Ozempic gastroparesis lawsuit actually claims

These cases are not arguing that GLP-1 drugs should never have existed. Instead, the core claim is a failure to warn. Plaintiffs allege that the manufacturers knew or should have known about the risk of severe, prolonged gastrointestinal injury, and that the warnings given to patients and prescribing doctors did not adequately reflect it.

Gastroparesis is worth explaining in plain terms. Think of the stomach as a conveyor belt that moves food along to the intestines. Gastroparesis is what happens when that belt slows dramatically or stalls, which can cause months of nausea, vomiting, bloating, severe pain, malnutrition, and repeat hospital visits.

The FDA has taken action in this area. In September 2023, the agency announced a safety-related labeling change adding a warning about ileus — a blockage that keeps food and liquid from passing through the intestines — to the semaglutide label. Notably, the FDA cautioned that its own adverse-event reports come from a population of uncertain size, so those reports alone cannot establish that a drug caused a given condition. That question is exactly what the courts are now working through.

Where the GLP-1 litigation stands right now

Federal GLP-1 injury cases are consolidated in a multidistrict litigation, or MDL. An MDL is best pictured as a shared pretrial workshop: hundreds or thousands of similar lawsuits are gathered before one judge so that discovery and expert fights happen once instead of separately in dozens of courthouses. Each case still keeps its own facts and its own value.

Here is the current picture, according to the U.S. Judicial Panel on Multidistrict Litigation’s September 1, 2026 report:

• MDL 3094 — In re: Glucagon-like Peptide-1 Receptor Agonists (GLP-1 RAs) Products Liability Litigation, before Judge Karen S. Marston in the Eastern District of Pennsylvania. 4,022 cases pending.
• MDL 3163 — a separate GLP-1 docket for non-arteritic anterior ischemic optic neuropathy (NAION), a form of sudden vision loss, also before Judge Marston. 216 cases pending.

As of that report, no global settlement has been announced in either docket, and no GLP-1 case has reached a jury verdict. In short, this litigation is still in the pretrial phase.

Why this month’s Rule 702 hearing matters so much

Courts do not let every expert say anything. Under Federal Rule of Evidence 702 — often called a Daubert review — the judge acts as a gatekeeper. Picture a referee checking whether each expert’s method is scientifically sound enough to be heard, before a jury ever hears a word of it.

The hearing scheduled in MDL 3094 for September 2026 covers general causation, along with warnings and federal preemption issues. General causation asks a broad question: can these drugs cause this injury in people at all? Specific causation, which comes later, asks a narrower one: did the drug cause this patient’s injury?

The stakes are straightforward. If the court excludes the plaintiffs’ general-causation experts, most of the cases in the MDL cannot proceed. However, if those experts are allowed to testify, the litigation moves toward bellwether trials — a small set of test cases tried first to show both sides how juries respond. No one can responsibly predict which way a judge will rule.

Which injuries the GLP-1 cases involve

The claims filed to date generally center on serious, documented gastrointestinal and vision injuries, including:

• Gastroparesis, or stomach paralysis, supported by objective testing
• Ileus and intestinal or bowel obstruction
• Severe, recurring vomiting leading to hospitalization or malnutrition
• Gallbladder disease and gallbladder removal
• Sudden vision loss diagnosed as NAION (handled in the separate MDL 3163)

Routine nausea in the first weeks on a GLP-1 drug is a known, labeled side effect. These lawsuits concern the severe and lasting end of the spectrum instead.

Who may qualify for a GLP-1 injury claim

Eligibility is fact-specific, so no blog post can tell you whether you have a case. Generally, though, the cases being filed share these features:

• Documented use of a GLP-1 receptor agonist — semaglutide (Ozempic, Wegovy, Rybelsus), tirzepatide (Mounjaro, Zepbound), liraglutide (Saxenda, Victoza), or dulaglutide (Trulicity)
• A qualifying injury diagnosed after starting the medication
• A diagnosis backed by objective medical testing; in this MDL, the court has emphasized that gastroparesis claims should rest on a properly performed gastric emptying study
• Medical and pharmacy records that connect the two
• A claim brought within the filing deadline that applies in the claimant’s state

That last point deserves emphasis. Statutes of limitations vary sharply from state to state, and some are short. Never assume a deadline you read about somewhere else applies where you live.

What to do if a GLP-1 drug hurt you

1. Talk to your doctor before changing anything. Do not stop a prescribed medication on your own. Your health comes first, and your medical record matters later.
2. Collect your records. Pharmacy printouts, prescription history, ER and hospital records, imaging, and gastric emptying study results are the backbone of these claims.
3. Write down the timeline. Note when you started the drug, when symptoms began, and every hospitalization. Memory fades; notes do not.
4. Report the side effect. You can file a report through FDA’s MedWatch program, which helps the agency spot safety signals.
5. Ask about deadlines early. Because limitation periods differ by state, a short conversation now can protect a claim you might otherwise lose.

How Trial Lawyers United helps in dangerous drug cases

Cases against pharmaceutical manufacturers are not won by filing paperwork and waiting. They are won by building a record. Trial Lawyers United handles dangerous drug litigation by preserving evidence early, assembling the medical and scientific experts a specific injury requires, and preparing every case as though it will be tried.

The firm is a national practice with its principal office in Phoenix, Arizona, and it works with local counsel where the rules require. Our attorneys also monitor FDA advisories and emerging safety data through the firm’s Emerging Litigation Watch program, which is how developments like this one reach clients early rather than late.

There is no cost to ask a question. Consultations are free, the firm advances litigation costs, and there is no fee unless there is a recovery.

Frequently Asked Questions

Is there an Ozempic settlement yet?

No. As of the JPML’s September 1, 2026 report, 4,022 cases were pending in MDL 3094 with no announced settlement program and no jury verdict in any GLP-1 case.

Does taking Ozempic mean I have a case?

No. A claim generally requires a diagnosed, documented injury, medical records tying it to the medication, and expert proof of causation. The court has not yet ruled on general causation in this litigation.

How long do I have to file a claim?

That depends on your state. Some deadlines run from the date of injury and others from the date you knew or reasonably should have known the medication may be involved. Because the periods can be short, it is better to ask early than to guess.

I used a GLP-1 drug for weight loss, not diabetes. Does that matter?

Claims have been brought by both diabetes patients and weight-loss users. What matters most is which drug you took, what injury you were diagnosed with, and what your records show.

What about vision loss?

Sudden vision loss claims involving NAION are being handled in a separate federal docket, MDL 3163, before the same judge. If you lost vision suddenly while taking a GLP-1 medication, mention it specifically when you call.

Talk it through with someone who does this work

A severe stomach injury can upend your job, your finances, and your health for years. You should not have to figure out a nationwide litigation on your own while you are still recovering.

If you or someone you love developed gastroparesis, a bowel obstruction, or sudden vision loss after taking a GLP-1 medication, Trial Lawyers United offers a free, confidential, no-obligation consultation to talk through your options. Call 602-560-5170 or contact us online — there is no fee unless we win.

Attorney Advertising. This article is provided for general informational purposes only and does not constitute legal advice. Reading it does not create an attorney-client relationship with Trial Lawyers United LLC. Every case is different, laws vary by state and change over time, and past results do not guarantee or predict a similar outcome in any future matter. Trial Lawyers United LLC maintains its principal office in Phoenix, Arizona; cases in other jurisdictions are handled in association with attorneys licensed in those jurisdictions. If you have a legal question about your specific situation, please consult a licensed attorney.